Phase 1 Eczema Trial, Recruiting NCT06946641 Sponsor: Shanghai Qilu Pharmaceutical Research and Development Center LTD Condition: Eczema
Back to Eczema

Phase 1 Eczema Trial, Recruiting

NCT06946641
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For Parts A, B, and C (earlier study phases):

  • Men and women between 18 and 45 years old (inclusive)
  • Men weighing at least 50 kg (about 110 lbs) and women weighing at least 45 kg (about 99 lbs), with a body mass index (BMI) between 18.0 and 30.0

For Part D (later study phase):

  • Men and women between 18 and 75 years old
  • People who have had a confirmed diagnosis of chronic eczema (atopic dermatitis) for at least 6 months before the screening visit
  • People whose eczema is considered moderate to severe based on specific medical scoring systems at the time of screening (confirm with trial site)
  • People who have experienced significant itching on most days in the week before their first dose (confirm with trial site)
  • People whose eczema did not improve enough with skin-applied (topical) treatments within the 6 months before screening

Who may not be able to join:

  • People with significant health conditions affecting the nervous system, heart, lungs, digestive system, kidneys, immune system, or other major body systems, as assessed by the study doctor
  • People whose heart electrical activity reading (ECG) shows an abnormal result above a certain level at screening (confirm with trial site)
  • People who smoke more than 5 cigarettes a day on average, or who currently use e-cigarettes
  • People who drink more than 14 units of alcohol per week (roughly 14 small glasses of wine or beers), or who test positive for alcohol at screening
  • People who have donated more than 400 mL of blood in the 3 months before screening, or more than 200 mL in the 4 weeks before screening, or who plan to donate blood during the study
  • People who have taken certain strong medications that affect how the body processes drugs (CYP3A4 inhibitors or inducers) within 4 weeks before screening (confirm with trial site)
  • People who have taken any prescription medicines, over-the-counter drugs, herbal remedies, or dietary supplements within 2 weeks before their first dose (or longer, depending on the medication)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: (+86) 18600489179

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Shanghai Qilu Pharmaceutical Research and Development Center LTD
Registry
ClinicalTrials.gov
Start date
31 March 2025
Est. completion
1 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence and severity of treatment emergent Adverse Events as assessed by CTCAE v5.0

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov